Tier 3 — preclinical

SIRT6 Ameliorates Atherosclerosis by Inhibiting M1 Macrophage Polarisation Through Deacetylated-TLR4

Jian Huang, Huiming Yi, Yanhui Wu, Wei Zhang, Xi Ai
Immunology 2026 178(3):481-493

Bibliography

PubMed
PMID 41795650
DOI
10.1111/imm.70129

Study snapshot

DesignApoE-knockout mouse atherosclerosis model plus LPS-stimulated macrophage experiments.
ModelWestern-diet ApoE-/- mice and RAW264.7 macrophages.
SampleMultiple animal and cellular experiments; exact group sizes not stated in the indexed abstract.
InterventionSIRT6 overexpression with TLR4 rescue experiments.
DurationModel-specific.
EndpointsAtherosclerotic plaque size; Blood lipids; M1/M2 macrophage polarization; TLR4 acetylation/protein levels

What the study showed, in plain terms

SIRT6 overexpression reduced plaque burden and inflammatory M1 macrophage polarization in an atherosclerosis mouse model, apparently by deacetylating and reducing TLR4.

Key findings

SIRT6 was reduced in atherosclerotic mice and inflammatory macrophages. Restoring SIRT6 reduced plaques and M1 polarization; TLR4 overexpression reversed the macrophage effect.

What this study can and cannot tell us

This is preclinical cardiovascular evidence, not a human cardiovascular-outcome trial of a SIRT6 activator.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability